<DOC>
	<DOCNO>NCT00774241</DOCNO>
	<brief_summary>This single arm study ass efficacy safety first line combination treatment Avastin + docetaxel patient HER2 negative metastatic breast cancer.Patients receive Avastin ( 15mg/kg iv every 3 week ) plus docetaxel ( 75mg/m2 every 3 week 6 cycle ) . The anticipated time study treatment disease progression , target sample size 100 individual .</brief_summary>
	<brief_title>PRIMADOS Study : A Study Avastin ( Bevacizumab ) Plus Docetaxel First Line Treatment Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>male female patient , &gt; =18 year age ; stage IV , HER2 negative metastatic breast cancer ; candidate taxanebased therapy ; ECOG performance status 02. prior chemotherapy metastatic breast cancer ; concomitant primary malignant disease , except adequately treated cervical cancer situ , basal squamous cell skin cancer within last 5 year ; suspicion CNS metastasis ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>